Since 2004, the combination of a diagnostic test for EGFR (EGFR PharmDxTM Kit, Dako, Cambridgeshire, UK), and the subsequent application of cetuximab or panitumumab in EGFR-positive colon carcinomas has been approved by FDA, reviewed in [94]. This evidence concerns the gene EGFR and colon carcinoma.